Deciphera's tumor-tackling oral med achieves 40% response rate, teeing up 2024 submission

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product.

Oral tumor treatment vimseltinib passed the primary endpoint in a phase 3 trial of patients with tenosynovial giant cell tumors (TGCTs), according to an announcement Monday.